3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Myelodysplastic Syndromes
5
Leukemia
5
Hodgkin Disease
4
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Hematologic Neoplasms
3
Blast Crisis
3
Anemia, Refractory, with Excess of Blasts
3
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Graft vs Host Disease
2
Congenital Abnormalities
2
Burkitt Lymphoma
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Thalassemia
1
Sezary Syndrome
1
Interventions
Nivolumab
21
pembrolizumab
19
Ipilimumab
14
Specimen Handling
12
Magnetic Resonance Spectroscopy
7
Opdualag
6
CTLA-4 Antigen
6
relatlimab
5
binimetinib
5
trametinib
4
Paclitaxel
4
dabrafenib
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
lifileucel
2
lenvatinib
2
fludarabine phosphate
2
fludarabine
2
encorafenib
2
capivasertib
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Mycophenolic Acid
×
30 days
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled